Eli Lilly

Eli Lilly Receives FDA Approval for New Weight-Loss Drug Zepbound, a Version of Diabetes Treatment Mounjaro

by
Eli Lilly Receives FDA Approval for New Weight-Loss Drug Zepbound, a Version of Diabetes Treatment Mounjaro

This medication, also known as tirzepatide, demonstrated significant weight loss potential, with dieters shedding between 40 to 60 pounds in trials. Eli Lilly has received approval from the U.S. Food and Drug Administration for its new weight-loss drug, Zepbound, a version of the well-known diabetes treatment Mounjaro Eli Lilly’s Zepbound joins Novo Nordisk’s Wegovy as … Read more

Eli Lilly’s Mounjaro Drug Shows Remarkable Weight Loss Results in Groundbreaking Study

by
Eli Lilly's Mounjaro Drug Shows Remarkable Weight Loss

In a groundbreaking study, when combined with rigorous diet and exercise regimes, participants experienced an astounding average weight loss of about 60 pounds, equivalent to a quarter of their total body weight. Eli Lilly’s diabetes drug Mounjaro, containing tirzepatide, proved highly effective in aiding people struggling with obesity and overweight issues Dr. Thomas Wadden, a … Read more

Eli Lilly’s Mirikizumab Shows Promise in Treating Crohn’s Disease, Faces Competition from AbbVie’s Skyrizi

by
Eli Lilly's Mirikizumab Shows Promise in Treating Crohn's Disease, Faces Competition from AbbVie's Skyrizi

The phase III VIVID-1 study demonstrated exceptional potential, meeting all primary and secondary benchmarks over a 52-week treatment span. Eli Lilly has unveiled promising results for its experimental drug, mirikizumab (Omvoh), in the treatment of moderate-to-severe Crohn’s disease (CD) Impressively, 51.4% of CD patients achieved clinical remission on the drug, a substantial surge compared to … Read more